UK metabolic peptide research education & trial intelligence
Evidence-led summaries of the molecules reshaping metabolic medicine — GLP-1, GLP-1/GIP, triple-agonist, amylin and growth-hormone-axis compounds — framed for UK regulation, trial literacy and safety. Not advice, not a supplier, not a dosing guide.
Sponsored — advertisement
PeptideBarn — UK research-peptide reference supplier
UK research-peptide supplier — batch-level Certificates of Analysis, HPLC ≥98% purity. Independent third-party certificates of analysis on every batch.
Sponsored — this is a paid advertisement from our disclosed commercial partner. · Research-use only, not for human administration.
Six authority clusters
A structured map of UK metabolic peptide research — regulation, trials, molecules, safety, mechanisms and conditions.
UK regulatory status
MHRA / EMA / FDA status, POM rules, advertising restrictions, online-pharmacy verification, grey-market and counterfeit risk.
Trial intelligence
Structured library of pivotal trials — SURMOUNT, SURPASS, STEP, SELECT, SUMMIT, FLOW, TRIUMPH, LEADER, SCALE — with limits, evidence grade and UK relevance.
Peptide evidence profiles
Molecule-by-molecule profiles for incretin agonists, amylin analogues, combination programmes and growth-hormone-axis compounds.
Safety signals
GI events, pancreatitis, gallbladder disease, retinopathy, thyroid C-cell warning, hypoglycaemia, psychiatric signals, lean-mass risk and counterfeit-product risk.
Mechanisms
GLP-1, GIP and glucagon receptor signalling, central appetite regulation, gastric-emptying tachyphylaxis, adipose remodelling, the GH axis and GHRH vs ghrelin secretagogues — pathways, related molecules and what each mechanism does not prove.
Condition evidence maps
Obesity, type 2 diabetes, MASLD/MASH, OSA, HFpEF, CKD, cardiovascular risk, sarcopenic obesity, post-discontinuation weight regain.
Featured static tools
All static. No APIs, no dosing calculators, no reconstitution guides, no supplier links.
Metabolic peptide evidence matrix
Filterable static matrix of molecules, mechanisms, UK status, trial phase, evidence grade and safety depth.
Regulatory status checker
Select a molecule and see UK / EU / US status, POM / investigational / research-only flag and human-use warning.
Trial comparison table
Side-by-side static table of pivotal trial designs, populations, endpoints and limitations.
Mechanism map
Static interactive view of incretin, glucagon, GH-axis and amylin pathways with linked molecules, trials and safety signals.
Featured peptide profiles
Profiles of the molecules driving 2026 metabolic research.
Tirzepatide
also known as LY3298176, Mounjaro
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly, demonstrating unprecedented mean body-weight reductions of approximately 22% in the landmark SURMOUNT-1 trial at 72 weeks.
Retatrutide
also known as LY3437943, triple agonist GLP-1/GIP/glucagon
A once-weekly triple GLP-1, GIP, and glucagon receptor agonist developed by Eli Lilly, demonstrating mean body-weight reductions of approximately 24% at 48 weeks in Phase 2 research.
Semaglutide
also known as Ozempic, Wegovy
A long-acting GLP-1 receptor monoagonist developed by Novo Nordisk, widely researched in STEP and SUSTAIN trials and MHRA-licensed in the UK for type 2 diabetes and chronic weight management.
Featured explainers
Plain-English, evidence-led answers to the highest-stakes questions UK readers ask.
The 2026 metabolic-peptide landscape
The incretin class has rewritten obesity and type-2 diabetes pharmacology. GLP-1 monoagonists (semaglutide, liraglutide, dulaglutide) reduced body weight and glycaemia and — in the SELECT trial of semaglutide in adults with overweight or obesity and pre-existing cardiovascular disease — reduced major adverse cardiovascular events. Dual GLP-1/GIP agonism (tirzepatide) and triple GLP-1/GIP/glucagon agonism (retatrutide, survodutide) have extended the magnitude of body-weight reduction in published phase 2/3 data, while amylin-based combinations (cagrilintide, CagriSema) and oral non-peptide programmes (orforglipron, danuglipron) are reshaping what "next-generation" means.
UK regulatory context. Tirzepatide (Mounjaro), semaglutide (Wegovy / Ozempic / Rybelsus), liraglutide (Saxenda / Victoza) and dulaglutide (Trulicity) are MHRA-licensed prescription-only medicines for specific indications. Retatrutide, cagrilintide, CagriSema, survodutide, pemvidutide, mazdutide, AOD-9604, HGH Fragment 176-191, CJC-1295 and ipamorelin are investigational or research-only in the UK and are not licensed for human therapeutic use.
Where to start: the semaglutide vs tirzepatide vs retatrutide evidence comparison; the UK POM context for incretin medicines; and the research-methods primer on reading phase 2 / phase 3 / CVOT data without overclaiming.
Editorial independence
Metabolic Peptides is editorially independent. We have no commercial relationship with any manufacturer of incretin medicines, any peptide supplier or any compounding pharmacy. We do not run an affiliate programme. We do not accept paid placement. See our editorial standards, conflict-of-interest policy, source-selection policy and why we do not provide dosing or sourcing advice.
Common questions
Short answers to the questions UK readers ask most. For deeper coverage see the trial intelligence hub and individual molecule profiles.
- What are metabolic peptides?
- Metabolic peptides are short amino-acid sequences that act on metabolic pathways — most prominently the incretin axis (GLP-1, GIP), the glucagon receptor, and the growth-hormone axis (GHRH and ghrelin receptors). The class spans MHRA-licensed prescription medicines (tirzepatide, semaglutide, liraglutide), investigational compounds in active clinical trials (retatrutide, cagrilintide, CagriSema, survodutide, pemvidutide, mazdutide), and research-only or preclinical compounds (AOD-9604, HGH Fragment 176-191, CJC-1295, ipamorelin).
- Which metabolic peptides are UK prescription-only medicines?
- In the UK, the following GLP-1-class molecules are MHRA-licensed prescription-only medicines for specific indications: tirzepatide (Mounjaro), semaglutide (Ozempic for type 2 diabetes; Wegovy for chronic weight management; Rybelsus for oral use), liraglutide (Saxenda for weight management; Victoza for type 2 diabetes), and dulaglutide (Trulicity for type 2 diabetes). Tesamorelin (Egrifta) is licensed in the US for HIV-associated lipodystrophy. All other compounds discussed here are investigational or research-only and are not licensed for human therapeutic use in the UK.
- Does this site sell, supply or recommend suppliers of any peptide or medicine?
- No. We do not sell, ship, prescribe, compound, broker or recommend suppliers of any peptide, medicine or compounded product. We do not rank, compare or link to peptide vendors, online pharmacies, telehealth services or compounding pharmacies. Prescription-only medicines should only be accessed through a qualified UK prescriber following appropriate clinical assessment. Investigational and research-only compounds must not be used outside an appropriately authorised research setting.
- Why does this site avoid dosing, titration or reconstitution advice?
- Dosing decisions for licensed medicines require qualified clinical assessment of the individual; we are not the right place for that. Investigational and research-only compounds must not be used outside an authorised research setting and would have no safe public-facing dose. Where we summarise titration schedules from named published trials, we present them as evidence-record artefacts only — not as prescriptions, recommendations or self-administration guides.